Human Islet Research Network

non-NIH Announcements

  • JDRF Requests for Applications (RFAs):

    • Novel Pathways and Targets for Beta Cell Regenerating Therapies in Diabetes
      The JDRF invites investigators to develop and conduct studies aimed at the discovery and validation of novel pathways and targets to promote the regeneration of functional human beta cell mass. Both T1D (type 1 diabetes) and T2D (type 2 diabetes) are characterized by declining function and loss of insulin-producing beta cells of the pancreatic islet; all T1D and the majority of T2D patients ultimately depend on insulin therapy due to the loss of adequate functional beta cell mass. Disease modifying regenerating therapies to restore functional beta cells mass are needed for both forms of diabetes. If you would like to submit an Industry Development and Discovery project LOI to this RFA, please contact Dr. Frank Martin to discuss prior to submitting an application.  JDRF.01.31.2019.pdf (59 downloads)

      Letter of Intent due: November 20, 2018 
      Application due:  January 31, 2019

    • Innovative Strategies To Demonstrate “Immunological Proof-of-Mechanism” And To Explore Early Outcome Measures In Immunotherapy Trials.

      JDRF is committed to addressing key hurdles in accelerating the clinical path towards approval of effective immunotherapies for the prevention and treatment of T1D. To that end, JDRF is soliciting letters of intent (LOIs) for the development of revised outcomes for clinical trials of immunotherapies that will allow faster and more efficient studies to establish proof-of-mechanism and proof-of-concept. Efforts are urgently needed in the T1D community to define measures that will allow evaluation of the therapeutic effects of candidate immune therapies in a shorter time frame and utilizing fewer subjects to evaluate therapeutic benefit.

      Letter of Intent due:  September 12, 2018
      Application due:  November 14, 2018
    • Therapeutic Development and Early Clinical Testing of T Cell Targeted Immunotherapies for the Treatment of Type 1 Diabetes

      The purpose of this request for applications (RFA) is to facilitate faster translation of important type 1 diabetes (T1D) related research findings into viable immune therapeutic candidates for human testing. This RFA intends to specifically support late stage preclinical development of promising candidate immune drug and biologic therapies. It is JDRF’s hope that projects successfully completed under this RFA will attract external partners for large scale trials towards regulatory approval of novel therapeutic candidates.

      Letter of Intent due:  October 8, 2018
      Application due:  January 7, 2019